EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Navigating the Post‐ BCMA / GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta‐Refractory Multiple Myeloma—A Multicenter Analysis

Maximilian Al-Bazaz iD, Winfried Alsdorf, Lisa Leypoldt, Piet Sonnemann, Christoph Schaefers iD, Jule Artzenroth, Marie Harzer, Abdulaziz Kamili, Leandra Bartke, Leon Cords, Jan Vorwerk, Theo Leitner und 11 weitere

American Journal of Hematology · 2026-07 · 101 (7) · 1433-1439

DOI: 10.1002/ajh.70297 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Hematology, online erschienen am 31.03.2026. Verfasst von Maximilian Al-Bazaz und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Hematology and Bone Marrow Transplantation With Division of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg,…. Hauptthemen laut MEDLINE: Multiple Myeloma, Dexamethasone, Bortezomib, Hydrazines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with relapsed/refractory multiple myeloma (RRMM) who are penta‐drug refractory, defined as resistant to two proteasome inhibitors, two immunomodulatory agents, and an anti‐CD38 monoclonal antibody, face a dismal prognosis, particularly after exposure to T‐cell–redirecting therapies. Selinexor, an oral exportin‐1 inhibitor, offers a distinct mechanism of action and may retain efficacy in this difficult setting. We conducted a retrospective analysis at six German tertiary centers (2023–2025) to evaluate the efficacy and safety of selinexor plus bortezomib and dexamethasone (SVd) in penta‐refractory MM after both BCMA‐ and GPRC5D‐targeted therapies. Eighteen patients were identified, with a median of seven prior lines of therapy. High‐risk cytogenetic abnormalities were present in seven cases, including del17p in six. The overall response rate (ORR) was 61%, including one complete, five very good partial, and five partial responses, and median progression‐free survival (PFS) was 4.3 months. Among nine patients (50%) with extramedullary disease (EMD), three achieved complete and one near‐complete EMD resolution. Two patients who had relapsed after CAR T‐cell treatment with idecabtagene vicleucel achieved partial and very good partial responses and were successfully transitioned to a second CAR T‐cell therapy with ciltacabtagene autoleucel. Hematologic toxicities under SVd were manageable, and no treatment‐related deaths occurred. SVd demonstrates meaningful activity in patients with penta‐refractory MM and prior failure of BCMA/GPRC5D‐targeted immunotherapies. The ORR of 61%, disease control in 78% of patients, and median PFS of 4.3 months support further evaluation of SVd in this highly refractory setting after failure of BCMA‐ and GPRC5D‐directed approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaDexamethasoneBortezomibHydrazinesAntineoplastic Combined Chemotherapy ProtocolsTriazolesB-Cell Maturation AntigenHumansFemaleMaleMiddle AgedAgedRetrospective StudiesImmunotherapyAged, 80 and overDrug Resistance, Neoplasm

Substanzen

DexamethasoneselinexorBortezomibHydrazinesTriazolesB-Cell Maturation AntigenTNFRSF17 protein, human

Autor:innen und Institutionen

  • Department of Oncology, Hematology and Bone Marrow Transplantation With Division of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Hematology, Oncology, University Medical Center Schleswig-Holstein, Campus Lübeck, University Cancer Center-Schleswig-Holstein, University of Lübeck, Lübeck, Germany.
  • Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.
  • Hannover Medical School, Clinic for Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hanover, Germany.
  • Department I of Internal Medicine, University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg, Germany.

ORCID-Profile: Maximilian Al-Bazaz, Christoph Schaefers, Katja Weisel, Ricardo Kosch

Zitieren

APA

Al-Bazaz, M., Alsdorf, W., Leypoldt, L., Sonnemann, P., Schaefers, C., Artzenroth, J., Harzer, M., Kamili, A., Bartke, L., Cords, L., Vorwerk, J., Leitner, T., Maulhardt, M., Brinkert, K., Brioli, A., Richardson, T., Holtick, U., Hillmann, S. M., Salwender, H., …, & Kosch, R. (2026). Navigating the Post‐ BCMA / GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta‐Refractory Multiple Myeloma—A Multicenter Analysis. American Journal of Hematology, 101(7), 1433-1439. https://doi.org/10.1002/ajh.70297

Vancouver

Al-Bazaz M, Alsdorf W, Leypoldt L, Sonnemann P, Schaefers C, Artzenroth J, et al. Navigating the Post‐ BCMA / GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta‐Refractory Multiple Myeloma—A Multicenter Analysis. American Journal of Hematology. 2026;101(7):1433-1439. doi:10.1002/ajh.70297

BibTeX
@article{AlBazaz2026,
  author = {Al-Bazaz, Maximilian and Alsdorf, Winfried and Leypoldt, Lisa and Sonnemann, Piet and Schaefers, Christoph and Artzenroth, Jule and Harzer, Marie and Kamili, Abdulaziz and Bartke, Leandra and Cords, Leon and Vorwerk, Jan and Leitner, Theo and Maulhardt, Markus and Brinkert, Kerstin and Brioli, Annamaria and Richardson, Tim and Holtick, Udo and Hillmann, Stefan M and Salwender, Hans and Khandanpour, Cyrus and Bokemeyer, Carsten and Weisel, Katja and Kosch, Ricardo},
  title = {Navigating the Post‐ BCMA / GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta‐Refractory Multiple Myeloma—A Multicenter Analysis},
  journal = {American Journal of Hematology},
  year = {2026},
  volume = {101},
  number = {7},
  pages = {1433--1439},
  doi = {10.1002/ajh.70297}
}
Kostenlos starten →